Nephros Inc. (NEPH)
NASDAQ: NEPHHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NEPH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $28.37M
- P/E (TTM)
- 15.35
- Forward P/E
- 11.86
- EPS (TTM)
- $0.17
- Dividend yield
- None
- 52-week range
- 2.61 – 6.42
- Day range
- 2.61 – 2.85
- Volume / Avg
- 50.23K / 48.33K
- Beta
- —
- Shares outstanding
- 10.87M
52-week range
NEPH stock today
Nephros (NEPH) closed at $2.61 on Nov 20, down 8.10% (-$0.23), versus the S&P 500's 3.70% decline. Shares are 59.3% below their 52-week high of $6.42, set on Nov 26, 2025 and 0.0% above the 52-week low of $2.61, near the bottom of the past year's range. NEPH is down 46.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.4%.
Nephros trades at 15.4x its trailing twelve-month earnings per share of $0.17. Its forward P/E of 11.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Nephros
Company profileNephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Robert Banks
- Headquarters
- South Orange, NJ
- Employees
- 36
- Website
- nephros.com
Financial highlights
Full financialsIn fiscal 2025, Nephros generated $18.8 million in revenue, up 32.7% from fiscal 2024. Net income was $1.2 million (+1513.5% year over year), for a net margin of 6.4% versus a median of -37.8% in the prior 5 years. Gross margin was 61.9% (up from 61.6%) and operating margin 6.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $18.79M | $14.16M | $14.24M | $9.97M | $10.22M |
| Growth | +32.67% | -0.53% | +42.74% | -2.37% | +19.34% |
| Net income | $1.19M | $74.00K | $-1.57M | $-7.11M | $-3.87M |
| EPS (diluted) | $0.11 | $0.01 | $-0.15 | $-0.73 | $-0.41 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$6.25+139.46%
- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.05 vs $0.02
- Surprise
- +150.00%
NEPH news
All NEPH news- Nephros, Inc. Director Lisa Nettis to Resign Effective November 26, 2026Nasdaq
- Nephros, Inc. Reports 18% Net Revenue Growth for Third Quarter 2026Nasdaq
- Nephros Announces Strong Third Quarter 2026 Financial ResultsGlobeNewswire
- Nephros Schedules Third Quarter 2026 Financial Results Conference CallGlobeNewswire
Nephros peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NSPRInspireMD Inc. | 0.54 | -12.97% | $29.23M | vs NEPH |
| XTNTXtant Medical Holdings Inc. | 0.21 | -2.82% | $29.49M | vs NEPH |
| TELATELA Bio Inc. | 0.6885 | -5.27% | $31.11M | vs NEPH |
| MDAISpectral AI Inc. Class A | 1.04 | -20.61% | $33.47M | vs NEPH |
| PLRZPolyrizon Ltd. | 9.31 | -8.42% | $22.61M | vs NEPH |
| DAVIDavion Healthcare Plc | 0.9001 | -9.99% | $22.50M | vs NEPH |
| SRTSSensus Healthcare Inc. | 2.26 | -4.24% | $37.20M | vs NEPH |
| PMIPicard Medical Inc. | 6.79 | +7.78% | $18.07M | vs NEPH |
Indexes, lists and sector
Nephros stock FAQ
What is Nephros's stock price today?
NEPH last traded at $2.61 as of Nov 20, 4:00 PM EST, down 8.10% on the day. Prices are delayed at least 15 minutes.
Does Nephros pay a dividend?
No. Nephros does not currently pay a regular cash dividend.
What is NEPH's P/E ratio?
NEPH trades at a trailing P/E ratio of 15.35 and a forward P/E of 11.86.
Who is Nephros's CEO?
Mr. Robert Banks is the chief executive officer of Nephros Inc., which has about 36 employees.
Has NEPH ever split its stock?
Yes. The most recent NEPH stock split was a 1-for-9 split on Jul 10, 2019, one of 2 splits on record.
What is the NEPH 52-week high?
The 52-week high for NEPH is $6.42 and the 52-week low is $2.61. The stock is currently 59.3% below its high.